• Je něco špatně v tomto záznamu ?

New mutation in erythroid-specific delta-aminolevulinate synthase as the cause of X-linked sideroblastic anemia responsive to pyridoxine

J. Kucerova, M. Horvathova, R. Mojzikova, P. Belohlavkova, J. Cermak, V. Divoky,

. 2011 ; 125 (4) : 193-7. [pub] 20110120

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027863

Grantová podpora
NS10281 MZ0 CEP - Centrální evidence projektů

BACKGROUND/AIMS: Congenital sideroblastic anemias (SA) are characterized by the presence of ringed sideroblasts in the bone marrow. The most common form is X-linked SA, which results from mutations in erythroid-specific δ-aminolevulinate synthase (ALAS2), the first enzyme in heme biosynthesis. In addition, autosomal recessive mutations in the erythroid-specific mitochondrial transporter SLC25A38 and glutaredoxin 5 (GLRX5) have recently been identified in SA patients with isolated erythroid phenotype. MATERIALS AND METHODS: We studied 5 young males with congenital SA from the Czech Republic. Mutation analysis was performed on the complete coding regions of 3 candidate genes (ALAS2, SLC25A38 and GLRX5), and the enzyme activity of ALAS2 was measured by a continuous spectrophotometric assay. RESULTS: We found the previously published R452H and R452C ALAS2 mutations in 3 patients. A novel K156E substitution in ALAS2 was discovered in 1 pyridoxine-responsive patient. The functional study showed that this substitution severely decreases ALAS2 enzyme activity. In 1 pyridoxine-refractory patient, no mutations were detected in ALAS2, SLC25A38 or GLRX5. CONCLUSION: Our report extends the list of known ALAS2 mutations, with the addition of a novel K156E substitution that is responsive to pyridoxine treatment and contributes to the general knowledge of congenital SA cases characterized worldwide.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027863
003      
CZ-PrNML
005      
20141211095641.0
007      
ta
008      
120817e20110120sz f 000 0#eng||
009      
AR
024    7_
$a 10.1159/000322870 $2 doi
035    __
$a (PubMed)21252495
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kucerova, Jana $u Department of Biology, Faculty of Medicine, Palacky University, Olomouc, Czech Republic.
245    10
$a New mutation in erythroid-specific delta-aminolevulinate synthase as the cause of X-linked sideroblastic anemia responsive to pyridoxine / $c J. Kucerova, M. Horvathova, R. Mojzikova, P. Belohlavkova, J. Cermak, V. Divoky,
520    9_
$a BACKGROUND/AIMS: Congenital sideroblastic anemias (SA) are characterized by the presence of ringed sideroblasts in the bone marrow. The most common form is X-linked SA, which results from mutations in erythroid-specific δ-aminolevulinate synthase (ALAS2), the first enzyme in heme biosynthesis. In addition, autosomal recessive mutations in the erythroid-specific mitochondrial transporter SLC25A38 and glutaredoxin 5 (GLRX5) have recently been identified in SA patients with isolated erythroid phenotype. MATERIALS AND METHODS: We studied 5 young males with congenital SA from the Czech Republic. Mutation analysis was performed on the complete coding regions of 3 candidate genes (ALAS2, SLC25A38 and GLRX5), and the enzyme activity of ALAS2 was measured by a continuous spectrophotometric assay. RESULTS: We found the previously published R452H and R452C ALAS2 mutations in 3 patients. A novel K156E substitution in ALAS2 was discovered in 1 pyridoxine-responsive patient. The functional study showed that this substitution severely decreases ALAS2 enzyme activity. In 1 pyridoxine-refractory patient, no mutations were detected in ALAS2, SLC25A38 or GLRX5. CONCLUSION: Our report extends the list of known ALAS2 mutations, with the addition of a novel K156E substitution that is responsive to pyridoxine treatment and contributes to the general knowledge of congenital SA cases characterized worldwide.
650    _2
$a 5-aminolevulátsynthetasa $x genetika $x metabolismus $7 D000624
650    _2
$a dospělí $7 D000328
650    _2
$a sideroblastická anemie $x farmakoterapie $x enzymologie $x genetika $7 D000756
650    _2
$a sekvence nukleotidů $7 D001483
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $7 D009154
650    _2
$a pyridoxin $x terapeutické užití $7 D011736
650    _2
$a sekvenční seřazení $7 D016415
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Horvathova, Monika
700    1_
$a Mojzikova, Renata
700    1_
$a Belohlavkova, Petra
700    1_
$a Cermak, Jaroslav
700    1_
$a Divoky, Vladimir
773    0_
$w MED00000045 $t Acta haematologica $x 1421-9662 $g Roč. 125, č. 4 (20110120), s. 193-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21252495 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20141211095741 $b ABA008
999    __
$a ok $b bmc $g 949905 $s 785209
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 125 $c 4 $d 193-7 $e 20110120 $i 1421-9662 $m Acta haematologica $n Acta Haematol $x MED00000045
GRA    __
$a NS10281 $p MZ0
LZP    __
$a Pubmed-20120817/11/03

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...